Latest Clinical trial Stories
BLUE BELL, Pa., March 28, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that CEO Dr. J. Joseph Kim will present an overview of the company at the 20th Annual Future Leaders in the Biotech Industry Conference taking place April 5th at the Millennium Broadway Hotel in New York City. Inovio PresentationApril 53:00-3:30 p.m. EDTA live and archived webcast of the presentation will be available on Inovio's homepage. About Inovio Pharmaceuticals, Inc....
Although chelation therapy with the drug disodium EDTA has been used for many years with limited evidence of efficacy for the treatment of coronary disease, a randomized trial that included patients with a prior heart attack found that use of a chelation regimen modestly reduced the risk of a composite of adverse cardiovascular outcomes, but the findings do not support the routine use of chelation therapy for treatment of patients who have had a heart attack, according to a study in the March...
Company to showcase its entire lineup of innovative EDC / eClinical solutions MINNETONKA, Minn., March 26, 2013 /PRNewswire/ -- MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, is pleased to announce its active participation in several upcoming clinical research events during the month of April. MedNet representatives will be providing demonstrations of the company's full lineup of flexible, practical and...
Marie-Paul Lachaud, D.V.M., to Expand European Operations KANSAS CITY, Kan. and BOSTON, March 26, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc., a biopharmaceutical company focused on licensing, developing and commercializing innovative prescription medications for cats and dogs (companion animals), today announced it has expanded its relationship with Marie-Paul Lachaud, DVM, as a consultant to the company who will lead drug evaluation and development in Europe. Dr. Lachaud is...
ROCKVILLE, Md., March 26, 2013 /PRNewswire-USNewswire/ -- Accelovance, Inc., a Maryland based contract research organization (CRO), was nominated for the 2013 ViE "Best CRO" Award for the sixth year in a row and is a confirmed finalist in this award category. Therapeutically focused on vaccines, infectious disease, immunology and oncology, Accelovance was a recipient of the award, as determined by an international panel of independent judges, previously in 2009, 2010 and 2011. The...
-- Data Predict OMS824 has Greater Brain Activity without Movement Side-Effects Seen with other PDE10 Inhibitors -- SEATTLE, March 26, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data from the multiple-ascending-dose (MAD) portion of the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. With these data and the previously announced successful single-ascending-dose portion of this...
Awarded at BioPharma Asia Industry Awards 2013 RALEIGH, N.C., March 25, 2013 /PRNewswire/ -- PRA, a leading clinical research organization, today announced it was voted "Best CRO" for the 3(rd) annual BioPharma Asia Industry Awards 2013. The winner was announced March 19 at an awards dinner in Singapore. "We are deeply honored to have been voted 'Best CRO'," said Kent Thoelke, PRA executive vice president, Scientific and Medical Affairs. "We have been working hard to continually...
Research Supported by Biopharmaceutical Companies is Boost to Texas Economy WASHINGTON, March 25, 2013 /PRNewswire/ -- Working in collaboration with university medical schools and science centers, local hospitals and clinical research facilities, America's biopharmaceutical companies have conducted more than 8,200 clinical trials of new medicines in Texas over the last 13 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). The...
Acquisition brings Shire a new phase 3 compound being investigated for the signs and symptoms of Dry Eye Disease LEXINGTON, Massachusetts, March 25, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it will acquire SARcode Bioscience Inc., a privately held biopharmaceutical company based in Brisbane, California. This acquisition continues to build Shire's presence in the ophthalmology therapeutic category and brings a new phase 3 compound -...
SAN DIEGO, March 25, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the European Commission (EC) has designated MST-188 as an orphan medicinal product for the treatment of sickle cell disease. This decision follows a positive opinion adopted by the Committee for Orphan Medicinal Products (COMP) recommending such designation. Brian M. Culley, Chief Executive Officer, said: "Now that we actively are recruiting patients in EPIC, our pivotal phase 3...
